查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1807210

藥物基因體學中的分子診斷市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、治療領域、地區和競爭細分，2020-2030 年）

Molecular Diagnostics In Pharmacogenomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Therapeutic Area, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球藥物基因體學分子診斷市場規模達6.864億美元，預計2030年將達到9.6932億美元，複合年成長率為6.12%。受個人化醫療和精準醫療需求日益成長的推動，全球藥物基因組學分子診斷市場正經歷強勁成長。藥物基因組學研究個別基因組成如何影響其對藥物的反應，它高度依賴分子診斷技術來識別影響藥物療效和安全性的基因變異。

市場概覽
預測期 2026-2030
2024年市場規模 6.864億美元
2030年市場規模 9.6932億美元
2025-2030 年複合年成長率 6.12%
成長最快的領域 試劑盒和檢測試劑
最大的市場 北美洲

分子診斷在幫助醫療保健提供者根據個別患者定製藥物治療方案，從而最大程度地減少藥物不良反應並最佳化治療效果方面發揮關鍵作用。儘管前景光明，但該市場仍面臨許多挑戰，例如監管複雜性、資料隱私問題，以及需要加強臨床驗證和醫療專業人員的教育。

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

測試成本高

主要市場趨勢

關注兒科和老年人群

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球藥物基因體學分子診斷市場的影響

第5章：全球藥物基因體學分子診斷市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按產品（試劑盒及檢測試劑、試劑、服務、其他）
    • 依治療領域（腫瘤學、神經系統疾病、心血管疾病、免疫系統疾病、傳染病、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美藥物基因體學分子診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲藥物基因體學分子診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區藥物基因體學分子診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲藥物基因體學分子診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲藥物基因組學分子診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：全球藥物基因體學分子診斷市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • Roche Diagnostics
  • QIAGEN
  • Thermo Fisher Scientific
  • Illumina, Inc.
  • Agilent Technologies
  • Abbott Molecular
  • Genomind
  • OneOme
  • Myriad Genetics
  • Invitae

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 30558

Global Molecular Diagnostics In Pharmacogenomics Market was valued at USD 686.40 Million in 2024 and is expected to reach USD 969.32 Million by 2030 with a CAGR of 6.12%. The global molecular diagnostics market in pharmacogenomics is experiencing robust growth, driven by the increasing demand for personalized medicine and precision healthcare. Pharmacogenomics, which studies how an individual's genetic makeup affects their response to drugs, relies heavily on molecular diagnostic technologies to identify genetic variations that influence drug efficacy and safety.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 686.40 Million
Market Size 2030USD 969.32 Million
CAGR 2025-20306.12%
Fastest Growing SegmentKits and Assays
Largest MarketNorth America

Molecular diagnostics play a critical role in enabling healthcare providers to tailor drug therapies to individual patients, thereby minimizing adverse drug reactions and optimizing therapeutic outcomes. Despite its promising outlook, the market faces challenges such as regulatory complexities, data privacy concerns, and the need for greater clinical validation and education among healthcare professionals.

Key Market Drivers

Growth in Healthcare Industry

The rapid growth of the healthcare industry is a pivotal driver fueling the expansion of the global molecular diagnostics in pharmacogenomics market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most significant and profitable segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which account for over USD 400 billion. As healthcare systems worldwide evolve to offer more personalized and effective treatments, there is an increasing demand for molecular diagnostic tools that enable tailored drug therapies based on an individual's genetic profile.

Hypertension and diabetes represent approximately 70% of all chronic disease cases. As India progresses through the third phase of the epidemiological transition characterized by degenerative, stress-related, and lifestyle-induced conditions the prevalence of chronic illnesses such as diabetes and cardiovascular diseases is rising significantly, driven in part by an ageing population. Rising prevalence of chronic and genetic disorders, coupled with the growing emphasis on precision medicine, is pushing healthcare providers and pharmaceutical companies to adopt pharmacogenomics-guided diagnostics. These diagnostics help optimize drug efficacy, minimize adverse drug reactions, and enhance overall patient outcomes, aligning with the healthcare industry's broader goals of improving quality of care and reducing costs.

Key Market Challenges

High Cost of Testing

The high cost of testing represents a significant challenge in the Global Molecular Diagnostics in Pharmacogenomics Market. Pharmacogenomic tests require sophisticated technology, specialized equipment, and skilled personnel, all of which contribute to substantial expenses. These elevated costs can limit the widespread adoption of pharmacogenomic testing, particularly in cost-sensitive healthcare systems and emerging markets.

Moreover, the financial burden associated with these tests often deters healthcare providers and patients from integrating pharmacogenomics into standard clinical practice. Although the promise of personalized medicine is compelling, the upfront investment needed for molecular diagnostics remains a critical barrier. Additionally, inconsistent reimbursement policies and limited insurance coverage across different regions exacerbate this challenge, leaving many patients to bear the cost out-of-pocket. This restricts access to pharmacogenomic testing and slows market growth.

Key Market Trends

Focus on Pediatric and Geriatric Populations

A significant emerging trend within the global molecular diagnostics in pharmacogenomics market is the growing focus on pediatric and geriatric populations. Currently, government policies on growth monitoring primarily target children under the age of five. Growth monitoring is a fundamental component of under-five clinics, where children are weighed regularly monthly during the first year, every two months in the second year, and quarterly thereafter up to the age of five to six years. These two demographic groups represent distinct patient segments with unique therapeutic needs and varying responses to medication, making personalized treatment approaches especially critical.

In pediatric care, molecular diagnostics enable precise identification of genetic factors that influence drug metabolism and efficacy in children. Given the physiological differences and developmental considerations in this population, pharmacogenomic testing helps clinicians optimize drug dosing and reduce the risk of adverse drug reactions, which are often more pronounced in younger patients.

Key Market Players

  • Roche Diagnostics
  • QIAGEN
  • Thermo Fisher Scientific
  • Illumina, Inc.
  • Agilent Technologies
  • Abbott Molecular
  • Genomind
  • OneOme
  • Myriad Genetics
  • Invitae

Report Scope

In this report, the Global Molecular Diagnostics In Pharmacogenomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Diagnostics In Pharmacogenomics Market, By Product:

  • Kits and Assays
  • Reagents
  • Services
  • Others

Molecular Diagnostics In Pharmacogenomics Market, By Therapeutic Area:

  • Oncology
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Molecular Diagnostics In Pharmacogenomics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Diagnostics In Pharmacogenomics Market.

Available Customizations:

Global Molecular Diagnostics In Pharmacogenomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Molecular Diagnostics in Pharmacogenomics Market

5. Global Molecular Diagnostics in Pharmacogenomics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Kits and Assays, Reagents, Services, Others)
    • 5.2.2. By Therapeutic Area (Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Molecular Diagnostics in Pharmacogenomics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Therapeutic Area
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Therapeutic Area
    • 6.3.2. Mexico Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Therapeutic Area
    • 6.3.3. Canada Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Therapeutic Area

7. Europe Molecular Diagnostics in Pharmacogenomics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Therapeutic Area
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Therapeutic Area
    • 7.3.2. Germany Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Therapeutic Area
    • 7.3.3. United Kingdom Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Therapeutic Area
    • 7.3.4. Italy Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Therapeutic Area
    • 7.3.5. Spain Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Molecular Diagnostics in Pharmacogenomics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Therapeutic Area
    • 8.3.2. India Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Therapeutic Area
    • 8.3.3. South Korea Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Therapeutic Area
    • 8.3.4. Japan Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Therapeutic Area
    • 8.3.5. Australia Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Therapeutic Area

9. South America Molecular Diagnostics in Pharmacogenomics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Therapeutic Area
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Therapeutic Area
    • 9.3.2. Argentina Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Therapeutic Area
    • 9.3.3. Colombia Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Therapeutic Area

10. Middle East and Africa Molecular Diagnostics in Pharmacogenomics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Therapeutic Area
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Therapeutic Area
    • 10.3.2. Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Therapeutic Area
    • 10.3.3. UAE Molecular Diagnostics in Pharmacogenomics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global Molecular Diagnostics in Pharmacogenomics Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Roche Diagnostics
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. QIAGEN
  • 16.3. Thermo Fisher Scientific
  • 16.4. Illumina, Inc.
  • 16.5. Agilent Technologies
  • 16.6. Abbott Molecular
  • 16.7. Genomind
  • 16.8. OneOme
  • 16.9. Myriad Genetics
  • 16.10. Invitae

17. Strategic Recommendations

18. About Us & Disclaimer